Ł. Strzępek, Patrycja Ciesielska, Katarzyna Karakiewicz-Krawczyk, A. Czerw
Due to the rarity of phyllodes breast tumors (particularly malignant tumors), a limited number of described cases and a lack of randomized studies, we currently do not have absolute guidelines for treating these types of tumors. The following article presents the case of a patient with a malignant phyllodes breast tumor, with numerous local recurrences after primary mastectomy and the effects of treatment. The course of the patient’s disease emphasizes the purposefulness and effectiveness of aggressive surgical treatment. In the article, the authors show that leaving even small abnormalities within the scar just to observation is not good practice; surgeons should try to remove all, even unclear, abnormalities.
{"title":"Malignant phyllodes tumor of the breast: case report, tumor characteristics, treatment approach","authors":"Ł. Strzępek, Patrycja Ciesielska, Katarzyna Karakiewicz-Krawczyk, A. Czerw","doi":"10.2217/bmt-2020-0036","DOIUrl":"https://doi.org/10.2217/bmt-2020-0036","url":null,"abstract":"Due to the rarity of phyllodes breast tumors (particularly malignant tumors), a limited number of described cases and a lack of randomized studies, we currently do not have absolute guidelines for treating these types of tumors. The following article presents the case of a patient with a malignant phyllodes breast tumor, with numerous local recurrences after primary mastectomy and the effects of treatment. The course of the patient’s disease emphasizes the purposefulness and effectiveness of aggressive surgical treatment. In the article, the authors show that leaving even small abnormalities within the scar just to observation is not good practice; surgeons should try to remove all, even unclear, abnormalities.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44236697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The impact of consanguinity on women's attitudes toward molecular testing of breast cancer in Saudi Arabia","authors":"B. Suliman","doi":"10.2217/BMT-2021-0002","DOIUrl":"https://doi.org/10.2217/BMT-2021-0002","url":null,"abstract":"","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"10 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43601916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Camejo, C. Castillo, A. Schiavone, A. Alfonso, D. Amarillo, F. Xavier, Esteban Alvarez, G. Krygier, L. Delgado
Male breast cancer (MBC) is a rare condition which, while sharing some similarities with breast cancer in women, has a unique disease profile of its own. Aim: To understand the characteristics of MBC and its management in Uruguay. Patients & methods: Retrospective observational study that included patients diagnosed with MBC. Results: 22 cases of MBC were found. The median age at diagnosis was 62.5 years. Symptoms included self-detected lump in 17 patients (77.3%) and nipple retraction in seven (22.7%). Ductal carcinomas of histological grade 2–3 were found in 20 patients (90.9%) and stage I–II disease was most commonly encountered (15 patients, 68.1%). Neoadjuvant chemotherapy, adjuvant chemotherapy, adjuvant radiotherapy and tamoxifen were offered to 16 (73%), 12 (54.5%), 17 (65.4%) and 20 (90.9%) patients, respectively. Conclusion: MBC behaves and is treated in many aspects like postmenopausal breast cancer. Further multi-institutional, prospective studies are needed for better understanding and management of male breast cancers.
{"title":"Male breast cancer diagnosis stages, treatment and survival in Uruguay: a retrospective analysis of a case series","authors":"N. Camejo, C. Castillo, A. Schiavone, A. Alfonso, D. Amarillo, F. Xavier, Esteban Alvarez, G. Krygier, L. Delgado","doi":"10.2217/bmt-2020-0035","DOIUrl":"https://doi.org/10.2217/bmt-2020-0035","url":null,"abstract":"Male breast cancer (MBC) is a rare condition which, while sharing some similarities with breast cancer in women, has a unique disease profile of its own. Aim: To understand the characteristics of MBC and its management in Uruguay. Patients & methods: Retrospective observational study that included patients diagnosed with MBC. Results: 22 cases of MBC were found. The median age at diagnosis was 62.5 years. Symptoms included self-detected lump in 17 patients (77.3%) and nipple retraction in seven (22.7%). Ductal carcinomas of histological grade 2–3 were found in 20 patients (90.9%) and stage I–II disease was most commonly encountered (15 patients, 68.1%). Neoadjuvant chemotherapy, adjuvant chemotherapy, adjuvant radiotherapy and tamoxifen were offered to 16 (73%), 12 (54.5%), 17 (65.4%) and 20 (90.9%) patients, respectively. Conclusion: MBC behaves and is treated in many aspects like postmenopausal breast cancer. Further multi-institutional, prospective studies are needed for better understanding and management of male breast cancers.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42912766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Nonpalpable breast lesions require localization, the gold standard for which is preoperative ultrasound-guided wire localization (PUGWL). Our unit also employs intraoperative ultrasound-guided wire localization (IUGWL). Here we evaluate PUGWL and IUGWL outcomes between 2014 and 2018. Primary outcomes were reoperation rates, complication rates and average specimen weights. Trainee feedback and cost analysis assessed IUGWL viability. Methods: Prospectively recorded data were collected. 511 patients were included (241 PUGWL and 270 IUGWL). Results: Reoperation rates: PUGWL 17.7% versus IUGWL 13.9% (p = 0.28) . Complication rates: PUGWL 5.8% versus IUGWL 6.6% (p = 0.72) . Average specimen weight: PUGWL 34.2 g versus IUGWL 24.3 g (p < 0.0001) . Trainees needed 15 supervised cases to be IUGWL competent. Performing IUGWL saves £289 per localization. Conclusion: IUGWL outcomes are comparable to those of PUGWL. IUGWL is cost-effective, patient-friendly and easy to learn and replicate. IUGWL merits wider dissemination and further planned research.
{"title":"Outcomes of intraoperative versus preoperative ultrasound-guided wire localization of nonpalpable breast lesions","authors":"P. Wignarajah, V. Papalouka, P. Forouhi","doi":"10.2217/BMT-2020-0013","DOIUrl":"https://doi.org/10.2217/BMT-2020-0013","url":null,"abstract":"Background: Nonpalpable breast lesions require localization, the gold standard for which is preoperative ultrasound-guided wire localization (PUGWL). Our unit also employs intraoperative ultrasound-guided wire localization (IUGWL). Here we evaluate PUGWL and IUGWL outcomes between 2014 and 2018. Primary outcomes were reoperation rates, complication rates and average specimen weights. Trainee feedback and cost analysis assessed IUGWL viability. Methods: Prospectively recorded data were collected. 511 patients were included (241 PUGWL and 270 IUGWL). Results: Reoperation rates: PUGWL 17.7% versus IUGWL 13.9% (p = 0.28) . Complication rates: PUGWL 5.8% versus IUGWL 6.6% (p = 0.72) . Average specimen weight: PUGWL 34.2 g versus IUGWL 24.3 g (p < 0.0001) . Trainees needed 15 supervised cases to be IUGWL competent. Performing IUGWL saves £289 per localization. Conclusion: IUGWL outcomes are comparable to those of PUGWL. IUGWL is cost-effective, patient-friendly and easy to learn and replicate. IUGWL merits wider dissemination and further planned research.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44002382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Franklin Castillero Rodriguez, O. Castillo-Fernandez, Maria Lim-Law, Cristiane Martin Palacios, L. Montano, Stephani Benitez, Jaime Samudio
The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.
{"title":"Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama","authors":"Franklin Castillero Rodriguez, O. Castillo-Fernandez, Maria Lim-Law, Cristiane Martin Palacios, L. Montano, Stephani Benitez, Jaime Samudio","doi":"10.2217/BMT-2021-0003","DOIUrl":"https://doi.org/10.2217/BMT-2021-0003","url":null,"abstract":"The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"1 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2021-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41428754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Gaughran, N. Aggarwal, B. Shadbolt, R. Stuart-Harris
Background: Cancer antigen 15.3 (CA15.3) is a commonly used tumor marker (TM) in metastatic breast cancer (MBC) but may not be raised. We assessed CA15.3, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125) and cancer antigen 19.9 in 193 MBC patients at diagnosis and follow-up. Materials & methods: This TM panel was measured approximately 3 monthly. Median follow-up was 29.3 months. Results: At diagnosis, the following TMs were raised: CA15.3 63.2%, CEA 37.3%, CA-125 45.0% and cancer antigen 19.9 17.3%. CA15.3 became raised later in 28/71. Raised TMs were less common in HER2+ tumors. CA-125 was frequently raised in triple negative tumors and was associated with pleural metastases. More raised TMs correlated with more sites of metastases and shorter survival. Conclusion: CEA and CA-125 showed benefit over CA15.3 alone in MBC and all three should be considered in MBC.
{"title":"The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer","authors":"G. Gaughran, N. Aggarwal, B. Shadbolt, R. Stuart-Harris","doi":"10.2217/bmt-2020-0015","DOIUrl":"https://doi.org/10.2217/bmt-2020-0015","url":null,"abstract":"Background: Cancer antigen 15.3 (CA15.3) is a commonly used tumor marker (TM) in metastatic breast cancer (MBC) but may not be raised. We assessed CA15.3, carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125) and cancer antigen 19.9 in 193 MBC patients at diagnosis and follow-up. Materials & methods: This TM panel was measured approximately 3 monthly. Median follow-up was 29.3 months. Results: At diagnosis, the following TMs were raised: CA15.3 63.2%, CEA 37.3%, CA-125 45.0% and cancer antigen 19.9 17.3%. CA15.3 became raised later in 28/71. Raised TMs were less common in HER2+ tumors. CA-125 was frequently raised in triple negative tumors and was associated with pleural metastases. More raised TMs correlated with more sites of metastases and shorter survival. Conclusion: CEA and CA-125 showed benefit over CA15.3 alone in MBC and all three should be considered in MBC.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45628189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Rahmati, M. Azami, Z. Jaafari, Nasrin Pouratar, Khairollah Asodollahi
Aims: The present study aimed to identify the most associated risk factors of breast cancer in Ilam province in 2015–2016. Materials & methods: In this case–control study, the case group consisted of 50 women with breast cancer with a definitive diagnosis from date 23 September 2015 to 22 September 2016. The two groups were group matched in terms of age. Data were collected through interviews and medical records. Results: According to the results, there was a significant relationship between the disease status and variables of family history, history of irregular menstrual cycles, history of breastfeeding, menopausal status, history of oral contraceptive pill consumption, BMI, menarche and number of pregnancies (p < 0.05). Conclusion: Regarding decisive risk factors of breast cancer, more studies with larger sample sizes that take into account more risk factors are necessary.
{"title":"An evaluation of the risk factors of breast cancer in women in Ilam Province: a case–control study based on hospital","authors":"S. Rahmati, M. Azami, Z. Jaafari, Nasrin Pouratar, Khairollah Asodollahi","doi":"10.2217/bmt-2020-0026","DOIUrl":"https://doi.org/10.2217/bmt-2020-0026","url":null,"abstract":"Aims: The present study aimed to identify the most associated risk factors of breast cancer in Ilam province in 2015–2016. Materials & methods: In this case–control study, the case group consisted of 50 women with breast cancer with a definitive diagnosis from date 23 September 2015 to 22 September 2016. The two groups were group matched in terms of age. Data were collected through interviews and medical records. Results: According to the results, there was a significant relationship between the disease status and variables of family history, history of irregular menstrual cycles, history of breastfeeding, menopausal status, history of oral contraceptive pill consumption, BMI, menarche and number of pregnancies (p < 0.05). Conclusion: Regarding decisive risk factors of breast cancer, more studies with larger sample sizes that take into account more risk factors are necessary.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47985405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren F Cornell, S. Mclaughlin, S. Pruthi, Dawn M. Mussallem
There are increasing numbers of elderly patients diagnosed with breast cancer. These patients are under-represented in available clinical trials, and as such, there are limited evidence-based guidelines for treatment in this population. Elderly patients have unique needs and management strategies should be tailored accordingly. This article reviews available literature regarding breast cancer management and special considerations in elderly patients.
{"title":"Special considerations of breast cancer management in the elderly","authors":"Lauren F Cornell, S. Mclaughlin, S. Pruthi, Dawn M. Mussallem","doi":"10.2217/bmt-2020-0023","DOIUrl":"https://doi.org/10.2217/bmt-2020-0023","url":null,"abstract":"There are increasing numbers of elderly patients diagnosed with breast cancer. These patients are under-represented in available clinical trials, and as such, there are limited evidence-based guidelines for treatment in this population. Elderly patients have unique needs and management strategies should be tailored accordingly. This article reviews available literature regarding breast cancer management and special considerations in elderly patients.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46882451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suneela Vegunta, S. Lester, S. Pruthi, Dawn M. Mussallem
Breast cancer (BC) is the most commonly diagnosed cancer and second most common cause of cancer death in US women. Family history and genetics are well-known BC risk factors, but they only account for 15–20% of BC cases. Therefore, in addition to family history, healthcare providers must consider a woman’s modifiable and nonmodifiable personal risk factors that are associated with an increase in BC risk. The World Cancer Research Fund/American Institute for Cancer Research estimate that 30% of BC cases in the US are preventable. Lifestyle education is imperative given the magnitude of BC occurrence. Evidence supports prevention as an effective, long-term strategy for reducing risk. Healthcare providers are key stakeholders in empowering patients to adopt a healthy lifestyle for primary BC prevention. In this paper, we review the available evidence on modifiable BC risk including weight management, nutrition, physical activity, alcohol and tobacco use and provide strategies to counsel patients on lifestyle modifications.
{"title":"Effects of major lifestyle factors on breast cancer risk: impact of weight, nutrition, physical activity, alcohol and tobacco","authors":"Suneela Vegunta, S. Lester, S. Pruthi, Dawn M. Mussallem","doi":"10.2217/BMT-2020-0033","DOIUrl":"https://doi.org/10.2217/BMT-2020-0033","url":null,"abstract":"Breast cancer (BC) is the most commonly diagnosed cancer and second most common cause of cancer death in US women. Family history and genetics are well-known BC risk factors, but they only account for 15–20% of BC cases. Therefore, in addition to family history, healthcare providers must consider a woman’s modifiable and nonmodifiable personal risk factors that are associated with an increase in BC risk. The World Cancer Research Fund/American Institute for Cancer Research estimate that 30% of BC cases in the US are preventable. Lifestyle education is imperative given the magnitude of BC occurrence. Evidence supports prevention as an effective, long-term strategy for reducing risk. Healthcare providers are key stakeholders in empowering patients to adopt a healthy lifestyle for primary BC prevention. In this paper, we review the available evidence on modifiable BC risk including weight management, nutrition, physical activity, alcohol and tobacco use and provide strategies to counsel patients on lifestyle modifications.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/BMT-2020-0033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45767205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Nuñez, F. C. González, Mónica Chapa Ibargüengoitia, Rosaura Eugenia Fuentes Corona, Antonio Carlos Hernández Villegas, Mariana Licano Zubiate, S. E. V. Manjarrez, Carlos Casian Ruiz Velasco
Papillary breast lesions are rare breast tumors that comprise a broad spectrum of diseases. Pathologically they present as mass-like projections attached to the wall of the ducts, supported by fibrovascular stalks lined by epithelial cells. On mammogram they appear as masses that can be associated with microcalcifications. Ultrasound is the most used imaging modality. On ultrasound papillary lesions appear as homogeneous solid lesions or complex intracystic lesions. A nonparallel orientation, an echogenic halo or posterior acoustic enhancement associated with microcalcifications are highly suggestive of malignancy. MRI has proven to be useful to establish the extent of the lesion. Core needle biopsy is the gold standard for diagnosis. Surgical excision is usually recommended, although treatment for papillomas without atypia is still controversial.
{"title":"Papillary lesions of the breast: a review","authors":"D. Nuñez, F. C. González, Mónica Chapa Ibargüengoitia, Rosaura Eugenia Fuentes Corona, Antonio Carlos Hernández Villegas, Mariana Licano Zubiate, S. E. V. Manjarrez, Carlos Casian Ruiz Velasco","doi":"10.2217/BMT-2020-0028","DOIUrl":"https://doi.org/10.2217/BMT-2020-0028","url":null,"abstract":"Papillary breast lesions are rare breast tumors that comprise a broad spectrum of diseases. Pathologically they present as mass-like projections attached to the wall of the ducts, supported by fibrovascular stalks lined by epithelial cells. On mammogram they appear as masses that can be associated with microcalcifications. Ultrasound is the most used imaging modality. On ultrasound papillary lesions appear as homogeneous solid lesions or complex intracystic lesions. A nonparallel orientation, an echogenic halo or posterior acoustic enhancement associated with microcalcifications are highly suggestive of malignancy. MRI has proven to be useful to establish the extent of the lesion. Core needle biopsy is the gold standard for diagnosis. Surgical excision is usually recommended, although treatment for papillomas without atypia is still controversial.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/BMT-2020-0028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43397495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：